Table 5.
C1‐INH prophylaxis and C1‐INH rescue by German centre
| Characteristic | Charité, Universitätsmedizin Berlin | HZRM Haemophilie Zentrum Rhein Main GmbH | Universitätsklinik Mainz | Hals‐Nasen‐Ohrenklinik und Poliklinik | Universitätsklinikum Essen | Klinikum der Johann‐Wolfgang Goethe Universitat | Universitätsklinikum Carl Gustav Carus |
|---|---|---|---|---|---|---|---|
| No. of patients | 37 | 25 | 11 | 7 | 6 | 4 | 3 |
| C1‐INH ongoinga long‐term or short‐term prophylaxis, n (%) | |||||||
| Yes | 9 (24.3) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 28 (75.7) | 21 (84.0) | 11 (100.0) | 7 (100.0) | 6 (100.0) | 4 (100.0) | 3 (100.0) |
| C1‐INH as rescue medicationb, n (%) | |||||||
| Yes | 7 (18.9) | 14 (56.0) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 3 (75.0) | 0 (0.0) |
| No | 30 (81.1) | 11 (44.0) | 10 (90.9) | 7 (100.0) | 6 (100.0) | 1 (25.0) | 3 (100.0) |
a
At IOS entry and/or during the follow‐up period.
b
C1‐INH rescue on at least one attack at IOS entry and/or during follow‐up period.
C1‐INH, C1‐inhibitor; IOS, Icatibant Outcome Survey.